Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.

Kaasinen E, Kuismin O, Rajamäki K, Ristolainen H, Aavikko M, Kondelin J, Saarinen S, Berta DG, Katainen R, Hirvonen EAM, Karhu A, Taira A, Tanskanen T, Alkodsi A, Taipale M, Morgunova E, Franssila K, Lehtonen R, Mäkinen M, Aittomäki K, Palotie A, Kurki MI, Pietiläinen O, Hilpert M, Saarentaus E, Niinimäki J, Junttila J, Kaikkonen K, Vahteristo P, Skoda RC, Seppänen MRJ, Eklund KK, Taipale J, Kilpivaara O, Aaltonen LA.

Nat Commun. 2019 Mar 19;10(1):1252. doi: 10.1038/s41467-019-09198-7.

2.

Dual roles of EZH2 in acute myeloid leukemia.

Skoda RC, Schwaller J.

J Exp Med. 2019 Apr 1;216(4):725-727. doi: 10.1084/jem.20190250. Epub 2019 Mar 19.

PMID:
30890555
3.

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC.

J Clin Invest. 2019 Mar 4;130:1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4.

4.

Accelerating myelofibrosis through loss of Dnmt3a.

Skoda RC.

Blood. 2018 Dec 27;132(26):2703-2704. doi: 10.1182/blood-2018-11-883470. No abstract available.

PMID:
30591541
5.

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.

Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK).

Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8.

6.

Nollmotzite, Mg[UV(UVIO2)2O4F3]·4H2O, the first natural uranium oxide containing fluorine.

Plášil J, Kampf AR, Škoda R, Čejka J.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2018 Aug 1;74(Pt 4):362-369. doi: 10.1107/S2052520618007321. Epub 2018 Jun 28.

7.

In vitro biomimetic engineering of a human hematopoietic niche with functional properties.

Bourgine PE, Klein T, Paczulla AM, Shimizu T, Kunz L, Kokkaliaris KD, Coutu DL, Lengerke C, Skoda R, Schroeder T, Martin I.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5688-E5695. doi: 10.1073/pnas.1805440115. Epub 2018 Jun 4.

8.

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A.

Nat Commun. 2018 Apr 12;9(1):1431. doi: 10.1038/s41467-018-03627-9.

9.

A Gain-of-Function Mutation in EPO in Familial Erythrocytosis.

Zmajkovic J, Lundberg P, Nienhold R, Torgersen ML, Sundan A, Waage A, Skoda RC.

N Engl J Med. 2018 Mar 8;378(10):924-930. doi: 10.1056/NEJMoa1709064.

10.

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.

Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.

11.

Nanocrystalline diamond protects Zr cladding surface against oxygen and hydrogen uptake: Nuclear fuel durability enhancement.

Škarohlíd J, Ashcheulov P, Škoda R, Taylor A, Čtvrtlík R, Tomáštík J, Fendrych F, Kopeček J, Cháb V, Cichoň S, Sajdl P, Macák J, Xu P, Partezana JM, Lorinčík J, Prehradná J, Steinbrück M, Kratochvílová I.

Sci Rep. 2017 Jul 25;7(1):6469. doi: 10.1038/s41598-017-06923-4.

12.

Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Meyer SC, Steinmann E, Lehmann T, Muesser P, Passweg JR, Skoda RC, Tsakiris DA.

Biomed Res Int. 2017;2017:9876819. doi: 10.1155/2017/9876819. Epub 2017 Jun 18.

13.

Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.

Lekovic D, Gotic M, Skoda R, Beleslin-Cokic B, Milic N, Mitrovic-Ajtic O, Nienhold R, Sefer D, Suboticki T, Buac M, Markovic D, Diklic M, Cokic VP.

Ann Hematol. 2017 Mar;96(3):393-404. doi: 10.1007/s00277-016-2890-9. Epub 2016 Dec 6.

PMID:
27924369
14.

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.

Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC.

J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Epub 2016 Jul 11.

15.

Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms.

Subotički T, Mitrović Ajtić O, Beleslin-Čokić BB, Nienhold R, Diklić M, Djikić D, Leković D, Bulat T, Marković D, Gotić M, Noguchi CT, Schechter AN, Skoda RC, Čokić VP.

Mol Carcinog. 2017 Feb;56(2):567-579. doi: 10.1002/mc.22517. Epub 2016 Jul 8.

PMID:
27341002
16.

JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.

Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, Hao-Shen H, Romanet V, Murakami M, Radimerski T, Dirnhofer S, Skoda RC.

Blood. 2016 Aug 11;128(6):839-51. doi: 10.1182/blood-2015-12-689216. Epub 2016 Jun 10.

17.

Layer Protecting the Surface of Zirconium Used in Nuclear Reactors.

Ashcheulov P, Skoda R, Skarohlíd J, Taylor A, Fendrych F, Kratochvílová I.

Recent Pat Nanotechnol. 2016;10(1):59-65.

PMID:
27018273
18.

Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.

Theocharides AP, Lundberg P, Lakkaraju AK, Lysenko V, Myburgh R, Aguzzi A, Skoda RC, Manz MG.

Blood. 2016 Jun 23;127(25):3253-9. doi: 10.1182/blood-2016-02-696310. Epub 2016 Mar 24.

19.

Pathogenesis of myeloproliferative neoplasms.

Skoda RC, Duek A, Grisouard J.

Exp Hematol. 2015 Aug;43(8):599-608. doi: 10.1016/j.exphem.2015.06.007. Epub 2015 Jul 21. Review.

20.

ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.

Hammarén HM, Ungureanu D, Grisouard J, Skoda RC, Hubbard SR, Silvennoinen O.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.

Supplemental Content

Loading ...
Support Center